Surevest LLC boosted its stake in Colgate-Palmolive (NYSE:CL) by 5.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,569 shares of the company’s stock after purchasing an additional 2,802 shares during the quarter. Colgate-Palmolive comprises about 1.5% of Surevest LLC’s holdings, making the stock its 20th biggest position. Surevest LLC’s holdings in Colgate-Palmolive were worth $3,901,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Evolution Wealth Advisors LLC grew its stake in Colgate-Palmolive by 158.4% in the third quarter. Evolution Wealth Advisors LLC now owns 323 shares of the company’s stock valued at $25,000 after acquiring an additional 198 shares during the period. Balentine LLC bought a new stake in Colgate-Palmolive during the 1st quarter valued at $36,000. Keebeck Wealth Management LLC bought a new stake in Colgate-Palmolive during the 2nd quarter valued at $41,000. Capital Advisory Group Advisory Services LLC acquired a new position in Colgate-Palmolive during the first quarter worth $45,000. Finally, Okabena Investment Services Inc. bought a new position in shares of Colgate-Palmolive in the second quarter valued at $51,000. 76.74% of the stock is owned by hedge funds and other institutional investors.

In other news, CTO Patricia Verduin sold 42,775 shares of Colgate-Palmolive stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $76.52, for a total value of $3,273,143.00. Following the completion of the transaction, the chief technology officer now owns 89,800 shares in the company, valued at $6,871,496. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Noel R. Wallace sold 85,929 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $76.37, for a total transaction of $6,562,397.73. Following the completion of the sale, the chief executive officer now directly owns 282,097 shares in the company, valued at approximately $21,543,747.89. The disclosure for this sale can be found here. Over the last three months, insiders have sold 256,994 shares of company stock valued at $19,678,851. 0.78% of the stock is owned by corporate insiders.

A number of research firms recently weighed in on CL. Deutsche Bank Aktiengesellschaft upped their target price on shares of Colgate-Palmolive from $75.00 to $78.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. TheStreet upgraded Colgate-Palmolive from a “c+” rating to a “b+” rating in a report on Friday, July 31st. Royal Bank of Canada reaffirmed a “buy” rating and set a $88.00 target price on shares of Colgate-Palmolive in a research report on Thursday, July 30th. Finally, Morgan Stanley increased their price target on Colgate-Palmolive from $78.00 to $80.00 and gave the company an “equal weight” rating in a research report on Monday, August 3rd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. Colgate-Palmolive presently has an average rating of “Hold” and a consensus price target of $75.27.

CL traded up $0.60 during trading on Friday, hitting $80.31. 2,963,577 shares of the company traded hands, compared to its average volume of 4,302,619. Colgate-Palmolive has a one year low of $58.49 and a one year high of $80.99. The stock’s fifty day moving average is $77.55 and its 200 day moving average is $73.84. The company has a quick ratio of 0.59, a current ratio of 0.92 and a debt-to-equity ratio of 9.40. The firm has a market cap of $68.86 billion, a P/E ratio of 26.86, a price-to-earnings-growth ratio of 4.63 and a beta of 0.59.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, July 31st. The company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.05. Colgate-Palmolive had a net margin of 16.13% and a return on equity of 559.34%. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.78 billion. During the same period in the previous year, the company earned $0.72 earnings per share. The company’s quarterly revenue was up .8% on a year-over-year basis. On average, equities research analysts forecast that Colgate-Palmolive will post 2.96 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Friday, October 23rd will be issued a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a yield of 2.19%. The ex-dividend date is Thursday, October 22nd. Colgate-Palmolive’s dividend payout ratio (DPR) is 62.19%.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Recommended Story: What is intrinsic value?

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.